Quick Asked: Tvardi Therapeutics Contact Us?
Last update: 04 May, 2024 
360 Views
Listing Results Tvardi Therapeutics Contact Us? Question Answers
Esco Ventures Announces the Launch of Carmine Therapeutics
20 7454 5110 Phone +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT and brings a wealth of biotech industry experience with his involvement in various biotech companies including Tvardi Therapeutics, Ziopharm
Vita Raises $32M to Advance Cell Therapies for LGMD, Other
Vita Therapeutics announced that it has raised $32 million in financing to advance its work into cell-based therapies for muscular dystrophy. “At Vita Therapeutics our mission is to deliver long-term disease-modifying cell engineered treatments for patients living with muscular dystrophies and other high unmet medical needs,” Douglas Falk, the company’s CEO, said in ...
Clinical Trial on Breast Cancer: TTI101 Clinical Trials
Tvardi Therapeutics, Incorporated has developed a compound, TTI-101, which can be given by mouth and acts as a direct inhibitor of STAT3. Administration of TTI-101 to mice demonstrated that it blocked growth of cancers of the breast, head and neck, lung, and liver and it was safe when administered at high doses to mice, rats, and dogs.
Tvardi Therapeutics Inc Company Profile and News
Company profile page for Tvardi Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information
Vita Therapeutics
Vita Therapeutics utilizes iPSCs to engineer specific cell types that are designed to replace those that are defective in patients. To deliver these cells we focus on two distinct methodologies: the autologous approach, a patient-specific therapy, and a hypoimmunogenic approach, a universal cell designed to be used for all patients.
Joseph Chen Vice President Tvardi Therapeutics
(832) 413-1362 HQ Phone (832) 413-1362 Company Tvardi Therapeutics Joseph Chen Current Workplace Tvardi Therapeutics Location 2450 Holcombe Blvd, Ste X, Houston, Texas, 77021, United States Industry Biotechnology, Pharmaceuticals, Healthcare Description Discover more about Tvardi Therapeutics Org Chart - Tvardi Therapeutics Phone Email Joseph Chen Vice ...
SEC FORM D/A
Name of Issuer; Tvardi Therapeutics, Inc. Street Address 1 Street Address 2; 7000 FANNIN STREET: SUITE 1960M: City State/Province/Country ZIP/PostalCode Phone Number of Issuer
Tvardi Therapeutics FierceBiotech
Tvardi Therapeutics Tvardi is focused on STAT3 inhibitors, a regulatory protein involved in a number of signaling pathways key to the survival and invasion of cancer cells CEO: Imran Alibhai, Ph.D.
TVARDI THERAPEUTICS, INC. SECURES $9 MILLION IN SERIES A
Company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases.. Houston, Texas. September 20, 2018 – Tvardi Therapeutics Inc. (“Tvardi”), a clinical-stage private biopharmaceutical company focused on the development of STAT3 inhibitors, announced today the completion of a $9 million ...
Tvardi Therapeutics Information Tvardi Therapeutics Profile
Where is Tvardi Therapeutics based? Top Tvardi Therapeutics Employees Imran Alibhai Chief Executive Officer Houston, Texas, United States View 4 tvardi.com gmail.com yahoo.com labspace.com 5+ 469-964-XXXX 714-362-XXXX 832-746-XXXX 415-977-XXXX 713-357-XXXX 972-484-XXXX Jeffrey Larson Research and Development Houston, Texas, United States ...
FORM D SEC
Name of Issuer; Tvardi Therapeutics, Inc. Street Address 1 Street Address 2; 7000 FANNIN STREET: SUITE 1960M: City State/Province/Country ZIP/PostalCode Phone Number of Issuer
Tvardi Therapeutics Crunchbase Company Profile & ...
832-413-1362 Headquarters Regions Greater Houston Area, Southern US. Founded Date 2017. Founders David Tweardy, Ron DePinho. Operating Status Active. Last Funding Type Series B. Legal Name Tvardi Therapeutics, Inc. Company Type For Profit. Phone Number 832-413-1362. Tvardi Therapeutics is focused on the development of inhibitors to STAT3, a key signaling
Tvardi Therapeutics hiring Clinical Project Manager (CPM
Sign in to save Clinical Project Manager (CPM) at Tvardi Therapeutics. Tvardi Therapeutics Houston, Texas, United States. Contact info Mobile phone number.
Startup Successes Rice Alliance
713-348-3443 Tvardi Therapeutics raised $74 Million in Series B Financing to Advance Clinical Programs. Contact Us: Email: [email protected] Phone: 713-348-3443 Sign up for our weekly email digest Office: McNair Hall, Suite 103 Map and Directions.
Fierce Biotech names Tvardi Therapeutics as one of its
HOUSTON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Tvardi Therapeutics (“Tvardi”) today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
Tvardi Therapeutics Employees, Board Members, Advisors
Employee Profiles. Number of Employee Profiles 3. Tvardi Therapeutics has 3 current employee profiles, including Co-Founder Ron DePinho. Ron DePinho Co-Founder. Jeno Gyuris Chief Scientific Officer & Chair of Scientific Advisory Board. David Tweardy President.
Tvardi Therapeutics racks up $74m Series B Venture
Tvardi Therapeutics racks up $74m Series B. Tvardi Therapeutics Inc, a biopharmaceutical company, has secured $74 million in Series B financing. Tvardi Therapeutics Inc, a biopharmaceutical company, has secured $74 million in Series B financing. Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital led the round.
Sonoma Biotherapeutics
Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary. September 16, 2021. Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases.
Tvardi Therapeutics Overview, News & Competitors
(832) 413-1362 Tvardi Therapeutics’s headquarters are in 2450 Holcombe Blvd, Ste X, Houston, Texas, 77021, United States What is Tvardi Therapeutics’s phone number? Tvardi Therapeutics’s phone number is (832) 413-1362 What is Tvardi Therapeutics’s official website? Tvardi Therapeutics’s official website is //tvarditherapeutics.com
Top Biotech companies in Houston List 2021 Updated
Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. Founded in 2017 and based in Houston, Texas, the company is led by experienced entrepreneurs, innovative scientists and dedicated physicians.
Press Release Archives AIMHI
July 24, 2020. News, Press Release. Tvardi Therapeutics Inc., a privately held, clinical-stage biopharmaceutical portfolio company of the AIM-HI Accelerator Fund focused on the development of STAT3 inhibitors, announced today over $5 million in non-dilutive grants to support the ongoing validation and clinical development of its....
Tvardi Therapeutics AIMHI
Tvardi Therapeutics, Inc. is a private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. Tvardi is focused on the key signaling molecule, STAT3, which is positioned at the intersection of many signaling pathways controlling gene networks integral to
PatientDerived Xenograft and Advanced In Vivo Models Core
713-798-1538 in Tvardi Therapeutics. LED is a compensated employee of StemMed, Ltd. AFFILIATIONS: Lacey E. Dobrolecki – LED Lester and Sue Smith Breast Center Dan L.Duncan Comprehensive Cancer Center dobrolec@ bcm.edu 713-798-1538 Baylor College of Medicine, One Baylor Plaza Houston, TX 77030 LDEV Disclosure Submit to dobrolec@ bcm.edu; anadulch@ bcm.edu
Tvardi Therapeutics LinkedIn
About us. Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and ...
Phase I study of TTI101, an Oral Inhibitor of Signal
Tvardi Therapeutics, Incorporated has developed a compound, TTI-101, which can be given by mouth and acts as a direct inhibitor of STAT3. Administration of TTI-101 to mice demonstrated that it blocked growth of cancers of the breast, head and neck, lung, and liver and it was safe when administered at high doses to mice, rats, and dogs.